The National Pharmaceutical Pricing Authority (NPPA) has allowed pharma major Sun Pharmaceuticals to change the manufacturer of two formulations of its hypertension drug combination olmesartan medoxomil, chlorthalidone and amlodipine, and permitted the company to manufacture the product in its own site.
MUMBAI, India and TEL AVIV, Israel, June 14, 2024 /PRNewswire/ -- Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, Sun Pharmaceutical Industries Limited, and includes its subsidiaries or associate companies) and Israel-based Moebius Medical Limited today presented data demonstrating the durability of pain relief achieved in symptomatic knee OA patients through 26 weeks post injection of MM-II. The results, presented today at EULAR 2024, are based on an analysis from the randomized, controlled, Phase 2b clinical study (NCT04506463).
Sun Pharma and Israel-based Moebius Medical Limited presented data demonstrating the durability of pain relief achieved in symptomatic knee OA patients through 26 weeks post injection of MM-II. The results, presented today at EULAR 2024, are based on an analysis from the randomized, controlled, phase 2b clinical study (NCT04506463).
Sildenafil, known by its brand name Viagra, may have benefits beyond treating erectile dysfunction. Recent research suggests it can help prevent memory-related problems by increasing cerebral blood flow and enhancing blood vessel function in those at risk of vascular dementia, a TOI report by Anuja Jaiswal stated.
Philogen and Sun Pharmaceutical (Sun Pharma) have announced the filing of a marketing authorisation application (MAA) with the European Medicines Agency (EMA) for Nidlegy, an investigational neoadjuvant therapy, for locally advanced, fully resectable melanoma.
Enforcement Report - Week of May 29, 2024
Indian drugmakers to see FY25 revenue boost in key US market
Taro shareholders approve merger with Sun Pharma